Significance of HIF-1α and CD105 in establishing oral squamous cell carcinoma associated with oral submucous fibrosis a distinct clinicopathological entity
Context: Oral squamous cell carcinoma associated with oral submucous fibrosis (OSCC with OSMF) is clinicopathologically a distinct entity. However, scientific proof in view of assessment of biomarkers of hypoxia and neoangiogenesis to differentiate them are lacking. The expression of hypoxia-inducible factor 1-α (HIF-1α) and CD105 in OSCC with and without OSMF possibly will be explicated along these lines.
Aim: This study aims to evaluate the molecular basis of hypoxia and neoangiogenesis in terms of immunohistochemical expression of HIF-1α and CD105 in OSCC with and without OSMF cases.
Settings and Design: A retrospective cohort.
Subjects and Methods: The study comprise of 203 histopathologically diagnosed surgically operated cases of OSCC retrieved from the departmental archives. The OSCC cases were subgrouped into two, OSCC with OSMF (Group I) and OSCC without OSMF (Group II). The evaluation of hypoxia and angiogenesis was carried out by immunohistochemical markers, HIF-1α and CD105. MVD is the parameter of angiogenesis expressed by CD105.
Statistical Analysis Used: Differences in CD105, and HIF-1α immunoreactivity between study groups were done using descriptive statistics using "Kruskal-Wallis test," "Mann-Whitney test." Statistical significance was set at P < 0.05.
Results: On comparison of MVD in Group I and II, statistically significant difference was found in MVD (8.88 ± 3.41, 16.13 ± 5.86, P = 0.0001). The HIF1-α expression was less in Group I (6.85 ± 2.62) as compare to Group II (7.22 ± 3.08) but the difference was statistically nonsignificant (P = 0.35).
Conclusions: The OSCC with OSMF is not only clinicopathologically distinct entity of OSCC but also diverse in its molecular pathogenesis as explicited by distinct expression of HIF-1 α and CD105.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:18 |
|---|---|
| Enthalten in: |
Journal of cancer research and therapeutics - 18(2022), 1 vom: 15. Jan., Seite 33-41 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Hande, Alka Harish [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
CD105 |
|---|
| Anmerkungen: |
Date Completed 07.04.2022 Date Revised 31.05.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.4103/jcrt.JCRT_591_20 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM339115602 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM339115602 | ||
| 003 | DE-627 | ||
| 005 | 20231226002202.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.4103/jcrt.JCRT_591_20 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1130.xml |
| 035 | |a (DE-627)NLM339115602 | ||
| 035 | |a (NLM)35381759 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Hande, Alka Harish |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Significance of HIF-1α and CD105 in establishing oral squamous cell carcinoma associated with oral submucous fibrosis a distinct clinicopathological entity |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 07.04.2022 | ||
| 500 | |a Date Revised 31.05.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Context: Oral squamous cell carcinoma associated with oral submucous fibrosis (OSCC with OSMF) is clinicopathologically a distinct entity. However, scientific proof in view of assessment of biomarkers of hypoxia and neoangiogenesis to differentiate them are lacking. The expression of hypoxia-inducible factor 1-α (HIF-1α) and CD105 in OSCC with and without OSMF possibly will be explicated along these lines | ||
| 520 | |a Aim: This study aims to evaluate the molecular basis of hypoxia and neoangiogenesis in terms of immunohistochemical expression of HIF-1α and CD105 in OSCC with and without OSMF cases | ||
| 520 | |a Settings and Design: A retrospective cohort | ||
| 520 | |a Subjects and Methods: The study comprise of 203 histopathologically diagnosed surgically operated cases of OSCC retrieved from the departmental archives. The OSCC cases were subgrouped into two, OSCC with OSMF (Group I) and OSCC without OSMF (Group II). The evaluation of hypoxia and angiogenesis was carried out by immunohistochemical markers, HIF-1α and CD105. MVD is the parameter of angiogenesis expressed by CD105 | ||
| 520 | |a Statistical Analysis Used: Differences in CD105, and HIF-1α immunoreactivity between study groups were done using descriptive statistics using "Kruskal-Wallis test," "Mann-Whitney test." Statistical significance was set at P < 0.05 | ||
| 520 | |a Results: On comparison of MVD in Group I and II, statistically significant difference was found in MVD (8.88 ± 3.41, 16.13 ± 5.86, P = 0.0001). The HIF1-α expression was less in Group I (6.85 ± 2.62) as compare to Group II (7.22 ± 3.08) but the difference was statistically nonsignificant (P = 0.35) | ||
| 520 | |a Conclusions: The OSCC with OSMF is not only clinicopathologically distinct entity of OSCC but also diverse in its molecular pathogenesis as explicited by distinct expression of HIF-1 α and CD105 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a CD105 | |
| 650 | 4 | |a hypoxia-inducible factor 1-α | |
| 650 | 4 | |a oral squamous cell carcinoma | |
| 650 | 4 | |a oral submucous fibrosis | |
| 650 | 7 | |a ENG protein, human |2 NLM | |
| 650 | 7 | |a Endoglin |2 NLM | |
| 650 | 7 | |a HIF1A protein, human |2 NLM | |
| 650 | 7 | |a Hypoxia-Inducible Factor 1, alpha Subunit |2 NLM | |
| 700 | 1 | |a Chaudhary, Minal S |e verfasserin |4 aut | |
| 700 | 1 | |a Gadbail, Amol R |e verfasserin |4 aut | |
| 700 | 1 | |a Gawande, Madhuri N |e verfasserin |4 aut | |
| 700 | 1 | |a Patil, Swati K |e verfasserin |4 aut | |
| 700 | 1 | |a Zade, Prajakta R |e verfasserin |4 aut | |
| 700 | 1 | |a Sharma, Preethi N |e verfasserin |4 aut | |
| 700 | 1 | |a Jaiswal, Shradha G |e verfasserin |4 aut | |
| 700 | 1 | |a Sonone, Archana M |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of cancer research and therapeutics |d 2005 |g 18(2022), 1 vom: 15. Jan., Seite 33-41 |w (DE-627)NLM174976801 |x 1998-4138 |7 nnns |
| 773 | 1 | 8 | |g volume:18 |g year:2022 |g number:1 |g day:15 |g month:01 |g pages:33-41 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.4103/jcrt.JCRT_591_20 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 18 |j 2022 |e 1 |b 15 |c 01 |h 33-41 | ||